HealthTree Podcast for Multiple Myeloma
210 episodes - English - Latest episode: 6 months ago - ★★★★★ - 13 ratingsHealthTree Podcast for Multiple Myeloma brings you patient-led interviews of the world's top multiple myeloma researchers. Call in live at showtime to (347) 637-2631 ask questions and to learn about the latest innovation in simple terms patients can understand.
Homepage Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Episodes
Myeloma Crowd Radio: Ola C. Landgren, Memorial Sloan Kettering Cancer Center
April 13, 2020 18:00 - 1 hour - 57.3 MBTo date, a select number of myeloma patients have become COVID-19 positive. What have they experienced and how have they fared? Dr. Ola Landgren of Memorial Sloan Kettering Cancer Center is living in New York City, a major hot spot in the United States for COVID-19. He joins us on Myeloma Crowd Radio to share his expderiences in treating COVID-19 positive patients and his suggestions for myeloma patients who have not been infected with COVID-19. Join us for this relevant and important program...
HealthTree Podcast for Multiple Myeloma: Ola C. Landgren, MSKCC
April 13, 2020 18:00 - 1 hour - 57.3 MBTo date, a select number of myeloma patients have become COVID-19 positive. What have they experienced and how have they fared? Dr. Ola Landgren of Memorial Sloan Kettering Cancer Center is living in New York City, a major hot spot in the United States for COVID-19. He joins us on HealthTree Podcast for Multiple Myeloma to share his expderiences in treating COVID-19 positive patients and his suggestions for myeloma patients who have not been infected with COVID-19. Join us for this relevant a...
Myeloma Crowd Radio: Joshua Richter, MD, Mount Sinai
March 20, 2020 18:00 - 1 hour - 79.9 MBThe coronavirus (COVID-19) is causing concern and disruption for normally healthy global citizens, but there are additional issues for multiple myeloma patients who are frequent visitors to hospitals and are often immunocompromised. Learn from myeloma expert Joshua Richter, MD of Mount Sinai about current recommendations for multiple myeloma patients regarding treatments, doctor visits, blood draws, stem cell transplant and other infusions in light of this unique global situation. Learn more ...
Myeloma Crowd Radio: Jennifer Saullo, MD, PharmD, Duke University
February 26, 2020 20:00 - 1 hour - 65.5 MBInfection is a leading cause of death for multiple myeloma patients and protection against infection is key, especially during stem cell transplant. At certain points during stem cell transplant, your immune system is at an all time low until your immune system “reboots” when stem cells are given back. Learn from transplant expert Jennifer Saullo, MD, PharmD of Duke University Medical Center as she shares ways to protect myeloma patients from infections before, during and after stem cell tran...
Myeloma Crowd Radio: Robert Z. Orlowski, MD, PhD, MD Anderson Cancer Center
January 30, 2020 17:00 - 1 hour - 61.9 MBWhat innovation is coming in 2020 in myeloma research? Dr. Robert Orlowski of the the MD Anderson Cancer Center shares the insights learned from the recent American Society of Hematology meeting and highlights leading edge research expected in 2020. There is a stunning amount of development happening in myeloma - immunotherapies like CAR T, bi-specific antibodies, tri-specific antibodies and antibody drug conjugates, new findings in precursor conditions like MGUS and smoldering myeloma, new t...
Myeloma Crowd Radio: Tanya Wildes, MD, Washington University
November 06, 2019 18:00 - 1 hour - 58.1 MBMany myeloma patients are elderly, with the average age of diagnosis being 68. If individuals are fit and active, they can typically receive the "standard of care" drugs such as stem cell transplant or triplet drug combinations. But many individuals may be frail or have other health conditions that would required doctors to adjust treatment accordingly. Dr. Tanya Wildes, MD of the Washington University Siteman Cancer Institute shares how treatment can be modified for more frail patients and h...
Myeloma Crowd Radio: Clifford Reid, PhD, Travera
October 23, 2019 17:00 - 1 hour - 55.2 MBHow much does a cancer cell weigh? And why does it matter? As cancer cells die, they change their weight in a matter of hours. A new device called the Suspended Microchannel Resonator (SMR) is a new technology that can measure a small change in the weight of a single cancer cell. The SMR machine can detect this change and tell whether a cancer cell has died of "natural causes" or if it was killed by a cancer drug. This allows rapid assessment of whether an individual patient is responding to ...
Myeloma Crowd Radio: Natalie Callander, MD, University of Wisconsin
September 30, 2019 15:00 - 57 minutes - 51.9 MBCellectar Biosciences is working on testing a radiosensitive therapy in blood cancers including multiple myeloma. Their product, CLR 131, targets the myeloma tumors by delivering a cytotoxic radioisotope, iodine-131 directly to the tumor cells. Phase I study results showed an overall mean survival rate of 26.2 months for relapsed/refractory myeloma patients (who had received on average 5.8 prior lines of therapy). The drug was given as a one or two-dose treatment as a single agent, given duri...
Myeloma Crowd Radio: Irene Ghobrial, MD, DFCI, PROMISE Study
September 04, 2019 17:00 - 1 hour - 54.9 MBIrene Ghobrial, MD of the Dana Farber Cancer Institute and Ivan Borrello, MD of Johns Hopkins are leading the largest study on precursor myeloma conditions that will include 50,000 patients and family members. The goal of the study is to detect myeloma early and see why and how patients who have MGUS and smoldering myeloma progress to active myeloma. The study is also seeking to understand the genetic, molecular and immune factors that lead to disease progression with the hope that this knowl...
Myeloma Crowd Radio: William Matsui, MD, University of Texas Dell Medical School
August 20, 2019 18:00 - 1 hour - 73.3 MBWhy is a myeloma specialist so important? What does it take to create a new myeloma research center from scratch? William Matsui, MD recently left Johns Hopkins to do just that. Dr. Matsui is the Deputy Director of the new University of Texas Dell Medical School's LIVESTRONG Cancer Institutes myeloma program. Learn what it takes to develop a new myeloma research center and lab and how it helps develop new strategies that could potentially extend lives. Dr. Matsui's unique focus on precursor s...
Myeloma Crowd Radio: Paul Richardson, MD, Dana Farber Cancer Institute
July 31, 2019 14:00 - 1 hour - 55.7 MBA new treatment called Selinexor was recently approved for highly relapsed multiple myeloma patients. Learn how experts like Dr. Paul Richardson of the Dana Farber Cancer Institute are using this new drug in their myeloma practice. Dr. Richardson will share how the drug works, when and how it should be used, potential side effects to watch out for and manage and why the new option is adding to patients' treatment choices. Paul Richardson, MD is RJ Corman Professor of Medicine at Harvard Med...
Myeloma Crowd Radio: Alexander Lesokhin, MD, Memorial Sloan Kettering CC
May 24, 2019 15:30 - 1 hour - 77.5 MBImmunotherapy is a major class of therapy that continues to expand in the myeloma clinic. Dr. Alexander Leshokin of Memorial Sloan Kettering Cancer Center explains the various types of immunotherapies: transplant, monoclonal antibodies, bi-specific antibodies, antibody drug conjugates, cellular therapies like CAR T, vaccines and where each type of treatment is at in the various stages of development. Dr, Alexander Lesokhin is Assistant Attending Physician at Memorial Hospital for Cancer and...
Myeloma Crowd Radio: Rafael Fonseca, MD, Mayo Clinic Scottsdale
May 20, 2019 20:30 - 1 hour - 55.8 MBSTEP therapy is an approach in managed medical care to minimize costs of prescription drugs. The program allows patients to begin therapy with the most cost-effective drugs and work their way up to more costly therapies only if necessary. It is also called "step protocol" or "fail first" and is a type of prior authorization requirement. Upward trends for prescription medications in the United States has led to an increased pressure on health care providers to keep medication costs down while ...
Myeloma Crowd Radio: David Siegel, MD, PhD, John Theurer Cancer Center
May 03, 2019 19:30 - 59 minutes - 53.8 MBCAR T therapy is becoming a hot area of early clinical trials for multiple myeloma patients, but most are personally customized for each patient. A company called Cellectis has developed an off-the-shelf CAR T that every patient can use. Instead of being an "autologous" CAR T treatment (where you use your own cells), this is also called an "allogeneic" CAR T, or a "donor"CAR T. Many of the current CAR T therapies are going after a target called b-cell maturation antigen (BCMA). This It is go...
Myeloma Crowd Radio: Yogesh Jethava, MD, University of Iowa
April 18, 2019 19:00 - 1 hour - 75.8 MBA new clinical trial is open combining low dose melphalan, a drug commonly used at high doses for stem cell transplant, and high dose intravenous Vitamin C. Learn more about how these two treatments work synergistically and why they have been combined in a clinical trial at the University of Iowa. The University of Iowa has unique experience with IV Vitamin C and Dr. Yogesh Jethava joins Myeloma Crowd Radio to share this fascinating open study now enrolling patients. Dr. Yogesh Jethava is A...
Myeloma Crowd Radio: Ravi Vij, MD, Washington University
February 06, 2019 20:00 - 1 hour - 55.1 MBA new monoclonal antibody called Isatuximab is advancing through clinical trials and is getting closer to FDA approval. This antibody targets CD38. Learn more from Dr. Ravi Vij of Washington University as he discusses the findings from recent clinical trials, how this drug will be used in the clinc and how it is different from other monoclonal antibodies previously approved. Dr. Vij was the senior author on the first Isatuximab paper published in Blood and has been involved in several clinica...
Myeloma Crowd Radio: Dr. Robert Z. Orlowski, MD Anderson Cancer Center 2019
January 08, 2019 16:00 - 1 hour - 57.2 MBMajor progress is being made in the field of multiple myeloma including a vast array of immunotherapy options. Learn about key findings from the recent ASH conference in addition to what we can look forward to in the coming year. Listen to myeloma expert Robert Z. Orlowski, MD, PhD of the MD Anderson Cancer Center as he reviews the up-and-coming choices for the clinic and those new treatments in clinical trials. Dr. Orlowski is Director of the Myeloma Section, Department of Lymphoma and Myel...
Myeloma Crowd Radio: Cesar Rodriguez, MD, Wake Forest University
December 14, 2018 20:00 - 1 hour - 65.2 MBTesting Your Individual Myeloma Tumor Against Available Myeloma Therapies Each myeloma patient's tumor is unique and can change over time. Dr. Rodriguez is using a new 3D organoid tumor modeling platform which allows the testing of over 50 myeloma treatment combinations against your specific tumor (including your bone marrow microenvironment) to identify which treatments will work best for your type of myeloma. This personalized approach will help you find useful drug combinations that will ...
Myeloma Crowd Radio: Frank Zhan, PhD and Yogesh Jethava, MD, University of Iowa
December 11, 2018 18:00 - 1 hour - 58.4 MBTargeting CD24 to Eliminate Myeloma Stem Cells Myeloma stem cells (or early progenitor cells before they become plasma cells) may not be killed with current myeloma therapies and could be the cause of relapse. Dr. Zhan has identified the presence of CD24 as a strong candidate as a cancer stem cell marker and believes that high CD24 levels lead to more aggressive myeloma and earlier death. His work will test patient samples for the presence of CD24 and assess outcomes while also identifying C...
Myeloma Crowd: David Chung, MD, PhD, Memorial Sloan Kettering Cancer Center
November 19, 2018 18:00 - 1 hour - 63.4 MBWhy do some multiple myeloma patients relapse early after stem cell transplant while others stay in remission for many years? The immune system may be a key factor. David Chung, MD, PhD of Memorial Sloan Kettering Cancer Center was recently selected as a Myeloma Crowd Research Initiative (MCRI) award recipient. The goal of the MCRI is to help optimize myeloma therapy for individual patients. Dr. Chung's research will review patients who have undergone stem cell transplant. He will study t...
Myeloma Crowd Radio: Dave Winfield and Don Baylor Jr. on your Most Valuable Plan
October 29, 2018 17:00 - 34 minutes - 30.9 MBIn the World Series and the world of baseball, a strategy for success means planning ahead - doing everything you can to come out a winner. In the world of multiple myeloma, that means being your best advocate and coming up with your Most Valuable Plan. Which doctor will you choose, what treatments will you receive and in what order? Having a game plan is essential to making sure you stay in the game. Join us as we talk with twelve-time MLB All-Sar and Hall-of-Famer Dave Winfield, whose close...
Myeloma Crowd Radio: Ashraf Badros, MD, University of Maryland
October 03, 2018 14:00 - 1 hour - 73.1 MBAfrican Americans are twice as likely to be diagnosed with the rare blood cancer called multiple myeloma than white Americans and other ethnicities. Why is this and what can we do to ensure that this population obtains their very best care? Learn more about the genetics, younger diagnosis and other unique features for these patients and what we could do to increase life expectancy. Dr. Ashraf Badros of the University of Maryland joins us for this important and life-saving show. Thanks to our...
Myeloma Crowd: Irene Ghobrial, MD, Dana Farber Cancer Institute
September 20, 2018 15:00 - 1 hour - 59.2 MBStand Up To Cancer has announced a $10 million award to a Stand Up To Cancer Dream Team focused on revolutionizing the treatment of multiple myeloma, an incurable blood cancer of plasma cells, through early detection of precursor conditions before they turn into full-blown disease. The team will be led by Irene Ghobrial, MD at Dana-Farber Cancer Institute (DFCI) in Boston and Ivan M. Borrello, MD, of Johns Hopkins University School of Medicine. The hypothesis of this proposal is that earl...
Myeloma Crowd Radio: Maria Chaudhry, MD, Ohio State University
September 13, 2018 15:00 - 1 hour - 54.2 MBAt last year's ASH meeting, there was excitement around a new antibody drug conjugate targeting a protein called BCMA from Glaxo Smith Klein. Results from their Phase I study showed that patients who had relapsed immunomodulators (like Revlimid), proteasome inhibitors (like Velcade) and even monoclonal antibodies (like daratumumab), responded when taking this drug alone (60% response rate). Learn more from Dr. Maria Chaudhry of Ohio State University about current studies using this new drug ...
Myeloma Crowd: Paul Richardson, MD, Dana Farber Cancer Institute
August 03, 2018 15:00 - 1 hour - 80.1 MBThe myeloma landscape is rapidly changing with many new advancements. Paul Richardson, MD of the Dana Farber Cancer Institute joins Myeloma Crowd Radio to share recent updates from major summer meetings including the American Society of Clinical Oncology and European Hematology Association meeting and several others. Thanks to our episode sponsor, Takeda Oncology.
Myeloma Crowd Radio: Brian McMahon of SparkCures (rescheduled)
July 30, 2018 17:00 - 1 hour - 67.3 MBHow do multiple myeloma patients get into clinical trials? Especially those using popular new science like CAR T therapy? Brian McMahon, founder of SparkCures shares tips and tricks to get into these trials. Brian is the founder of SparkCures, a multiple myeloma clinical trial finder tool that simplifies the process. Brian shares his experience helping individual myeloma patients join these trials and will share the ins and outs of clinical trial participation. Join us and call in with questi...
Myeloma Crowd Radio: Muhamed Baljevic, MD, University of Nebraska Medical Center
May 28, 2018 19:00 - 1 hour - 59.5 MBMany multiple myeloma patients can become resistant to an important class of myeloma drugs called proteasome inhibitors. Researchers found that expression of MUC20 could help predict how sensitive or resistant patients would be to proteasome inhibitors and found that MUC20 protein could be potentially impacted by an already FDA-approved drug offered by Amgen. Learn more from Dr. Muhamad Baljevic of the University of Nebraska Medical Center about how this new drug is being used in a Phase I/...
Myeloma Crowd Radio: HealthTree With Rafael Fonseca, MD, Mayo Clinic
May 18, 2018 21:00 - 1 hour - 60.4 MBA new tool for multiple myeloma patients is coming in June! Join us as we discuss the Myeloma Crowd's new initiative called HealthTree with Rafael Fonseca, MD of the Mayo Clinic in Scottsdale. HealthTree will help myeloma patients understand their personally relevant treatment options, find clinical trials, track lab data and help accelerate research towards a cure. Over 80% of myeloma patients are treated by general oncologists, yet data shows that patients who see myeloma specilists ca...
Myeloma Crowd Radio: Luciano Costa, MD, PhD, University of Alabama
April 16, 2018 17:00 - 1 hour - 54.5 MBAdequate treatment of multiple myeloma at diagnosis is a key issue for patients because their first remission is typically the longest and most durable. Dr. Luciano Costa of the University of Alabama joins Myeloma Crowd Radio to discuss a trial testing some of the best therapies for myeloma up-front: lenalidomide, dexamethasone, carfilzomib and daratumumab followed by a stem cell transplant. The same four drugs will be used after transplant as "consolidation" therapy. The goal is to understa...
Myeloma Crowd Radio: Veronika Bachanova, MD, PhD, University of Minnesota
March 12, 2018 19:30 - 51 minutes - 46.3 MBNatural killer cells are the body's way of eliminating cancerous cells. When a myeloma patient's immune system is too weak, the natural killer cells can't effectively do their job to eliminate myeloma. A study is now being done to test donor natural killer cells in relapsed myeloma patients. The natural killer cells are collected and combined with IL-2 to help them grow and expand. Elotuzumab is used to help the NK cells migrate to the myeloma tumor and has anti-myeloma effect on its own. Lea...
Myeloma Crowd Radio: William Matsui, MD, Johns Hopkins University
February 16, 2018 19:30 - 1 hour - 63.7 MBAllogeneic stem cell transplant was the first ever immunotherapy available for mulitple myeloma patients. Dr. Matsui shares how the Johns Hopkins allo transplant procedure has significantly improved safety concerns. His research is now focused on extending and deepening remissions with a new immunotherapy antibody given with transplant. Dr. Matsui will also share his latest research on precursor myeloma cells (called myeloma stem cells) and how they can be targeted before growing into full bl...
Myeloma Crowd Radio: Martin Kaiser, MD, The Institute of Cancer Research, UK
February 11, 2018 15:00 - 39 minutes - 35.1 MBDr. Martin Kaiser joins Myeloma Crowd Radio to share more about the latest advances in myeloma treatment in the United Kingdom and how the use of myeloma genomic data with thousands of patients in the UK is furthering new insights in myeloma care. Thanks to our episode sponsor, SparkCures. SparkCures provides an easy way to find and join multiple myeloma clinical trials.
Myeloma Crowd Radio: Robert Orlowski, MD, PhD, MD Anderson Cancer Center
January 05, 2018 17:00 - 1 hour - 57.7 MBThe year 2018 promises to be an exciting one in multiple myeloma research. Learn what about key findings from the recent ASH conference in addition to what we can look forward to in the coming year. With the explosion of immunotherapy and combination approaches now in the clinic and in clinical trials, the choices are greatly expanding for myeloma patients. Listen to myeloma expert Robert Z. Orlowski, MD, PhD of the MD Anderson Cancer Center as he reviews the up-and-coming choices for the cl...
Myeloma Crowd Radio: Diahanna Valentine, Critical Care Financial Consulting
October 17, 2017 17:00 - 1 hour - 56.9 MBMultiple myeloma treatment can cause "financial toxicity" for patients who are trying to pay for care that will give them optimal outcomes. Diahanna Valentine joins the Myeloma Crowd to discuss financial resources that are available to myeloma patients in this informative. show. Diahanna is Owner and Founder of Critical Care Financial Consulting, LLC which takes a holistic approach to managing your finances in the face of a critical or chronic illness. She is an 18+ year Financial Advisor, ...
Myeloma Crowd Radio: Irene Ghobrial, MD & Salomon Manier, MD, PhD, Dana Farber
September 27, 2017 16:00 - 49 minutes - 44.5 MBMyeloma patients can't wait until blood-based "liquid biopsies" replace the dreaded bone marrow biopsy. Painful and intrusive, the bone marrow biopsy is today's "standard" of myeloma testing to determine levels of myeloma disease burden in patients. These biopsies need to be performed at diagnosis, relapse and repeated every so often to determine response to treatment. Researchers at the Dana Farber Cancer Institute and the Harvard School of Medicine are creating a blood-based test that could...
Myeloma Crowd Radio: Michael O'Dwyer, MD, National University of Ireland
August 25, 2017 16:00 - 1 hour - 61 MBSugar molecules could act as a smoke screen for multiple myeloma cells, essentially hiding them from the immune system. The surface sugars, called sialic acids, can mark the cancer cells as “self” cells, giving the immune system the signal to ignore them. Dr. Michael O'Dwyer is Director of the Blood Cancer Network Ireland and Professor of Hematology at the National University of Ireland Galway. Dr. O'Dwyer has expertise in the glycosylation process as it relates to multiple myeloma. The gl...
Myeloma Crowd Radio: Sagar Lonial, MD, Winship Cancer Institute
July 19, 2017 18:00 - 1 hour - 58.7 MBThe recent meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA) occurred recently in May and June. There are a wealth of updates on up-and-coming therapies, use of combinations to improve outcomes, strategies to reduce side effects and much more from myeloma specialists across the world. Dr. Sagar Lonial will join us to share an overview of the major themes in myeloma advances from his leading-edge perspective. Dr. Sagar Lonial is an in...
Myeloma Crowd Radio: Drs. Anja Seckinger and Dirk Hose, University of Heidelberg
May 24, 2017 15:00 - 1 hour - 56 MBMany patients are familiar with the monoclonal antibodies daratumumab and elotuzumab. These target a specific protein on the surface of myeloma cells. A new approach is in progress to target both a protein on the surface of myeloma cells (BCMA) while also activating the immune system's T cells. This is called a bi-specific antibody, going after two targets at the same time. Join us to learn more about this fascinating approach from German researchers Anja Seckinger, MD and Dirk Hose, MD of th...
Myeloma Crowd Radio: Elisabet Manasanch, MD, MD Anderson Cancer Center
April 26, 2017 19:00 - 1 hour - 71.2 MBCan the genetics of myeloma or other clinical factors predict who will progress from early conditions like MGUS and smoldering myeloma to active myeloma? Dr. Elisabet Manasanch of the MD Anderson Cancer Center is hosting a study in partnership with Signal Genetics/Quest to determine what is meaninfgul (or not) in determining who is most likely to progress and is thus most likely to receive treatment. Dr. Manasanch is also studying the new monoclonal antibody Isatuximab in a clinical trial for...
Myeloma Crowd Radio: Dr. Guido Tricot, MD, PhD, University of Iowa
March 31, 2017 19:00 - 59 minutes - 53.8 MBToday's myeloma therapy can help patients gain remission, but the combinations can cause their own side effects because they target normal cells as well as cancer cells. Investigators at the University of Iowa including Dr. Guido Tricot and Dr. Frank Zhan have tested mega-doses of Vitamin C in combination with the standard chemo melphalan and found that the Vitamin C can kill myeloma cells while not affecting normal cells. Additionally, it boosts the power of melphalan, so that melphalan can ...
Myeloma Crowd Radio: Gareth Morgan, MD, FRCP, PhD, UAMS Myeloma Instititue
March 24, 2017 17:00 - 1 hour - 60.1 MBDr. Gareth Morgan of the UAMS Myeloma Institute joins us to share more about the Myeloma Genome Project, a global effort to create a broad collection of high-quality genomic and clinical data from multiple myeloma patients to improve diagnosis, prognosis and treatment. The project will compile a broad set of genetic data and resulting outcomes to develop a strategy to segment patients into groups for more specific types of treatment. It also hopes to develop specific tests for disease-associ...
Myeloma Crowd Radio: Heather Landau, MD, Memorial Sloan Kettering Cancer Center
February 28, 2017 16:00 - 50 minutes - 45.3 MBAbout 10-20% of multiple myeloma patients will develop a condition called amyloidosis during the course of their disease. Amyloidosis is a disease caused by protein buildup in organs such as the heart, kidneys, liver or intestines, leading to organ damage and complications associated with some multiple myeloma treatments. There are three major types of amyloidosis: primary, secondary, and hereditary. Each type of amyloidosis is classified by its underlying causes and the type of protein that...
Myeloma Crowd Radio: Cristina Gasparetto, MD, Duke Cancer Institute
February 17, 2017 18:00 - 1 hour - 58.7 MBAllogeneic stem cell transplant is rarely used in multiple myeloma treatment, but for younger patients with high-risk myeloma, it could be a highly effective strategy with durable outcomes. Dr. Cristina Gasparetto from Duke University shares the rationale of this approach for a subset of myeloma patients and how improvements in reducing allo side effects (like graft vs. host disease) are making this type of transplant easier. Thanks to our episode sponsor, Takeda Oncology
Myeloma Crowd Radio: Ola Landgren, MD, PhD, Memorial Sloan Kettering Cancer Ctr
January 12, 2017 19:00 - 1 hour - 63.3 MBFor the last 50 years, myeloma studies have relied on myeloma progression measurements like complete response (CR) or progression free survival (PFS) to tell whether new treatmets are working (or not). Myeloma patients are now living longer because of new treatment advances, which is a huge blessing. But it is also a challenge for research. If the average patient is living 8-10 years, how can studies be performed and show results in the 2-3 year range so that the new drugs can be approved qui...
Myeloma Crowd Radio: Dr. Robert Orlowski, MD, PhD, MD Anderson Cancer Center
January 05, 2017 20:00 - 1 hour - 68.3 MBThe year 2017 promises to be an exciting one in multiple myeloma research. With so many new types of therapies in the clinic like immunotherapies, specific inhibitors and variations of combinations, the choices are expanding for myeloma patients. Listen to myeloma expert Dr. Robert Z. Orlowski of the MD Anderson Cancer Center as he reviews the up-and-coming choices for the clinic and those new treatments in clinical trials. Special thanks to our episode sponsor, Takeda Oncology.
Myeloma Crowd Radio: Ask the Experts at the St. Louis Myeloma Crowd Round Table
December 30, 2016 20:00 - 25 minutes - 22.5 MBIt's a rare opportunity to have a panel of myeloma experts available to answer any myeloma patient question. Experts at our Myeloma Crowd Round Tables answered common patient questions at our meeting in St. Louis. Listen in to learn more about a wide variety of topics with experts that have over 80 years treating myeloma including: Guido Tricot, MD, PhD (University of Iowa), Morie Gertz, MD (Mayo Clinic), Keith Stockerl-Goldstein, MD (Washington University), and Ravi Vij, MD (Washington Univ...
Myeloma Crowd Radio: Ivan Borrello, MD, Johns Hopkins School of Medicine
December 27, 2016 06:00 - 20 minutes - 18.1 MBOne of the two projects funded by the Myeloma Crowd Research Initiative is an immunotherapy called MILs (marrow infiltrating lymphocytes). For high risk myeloma patients, their T-cells are taken out, grown up a hundred fold in the presence of their tumor and then given back a post-transplant. Dr. Borrello gives us an update on his open clinical trlal for high risk patients and shares how is also using the MILs with allogeneic transplant and other future combinations (like with checkpoint inhi...
Myeloma Crowd Radio: Craig Cole, MD, University of Michigan
November 17, 2016 18:00 - 1 hour - 71.1 MBAt the University of Michigan, Dr. Craig Cole is working on a collaboration with the MMRC to perform genomic sequencing on 500 hundred relapsed and refractory myeloma patients over a two year period. The goal is to share each patient's genomic profile to identify patient-specific treatment options. The study will be open at 11 myeloma academic centers to begin, with more to open in the future. The tissue samples collected at these centers are shipped to the University of Michigan Comprehensiv...
Myeloma Crowd Radio: Dr. Sergio Giralt, MD, Memorial Sloan Kettering Cancer Ctr
November 11, 2016 22:00 - 1 hour - 57.2 MBAccording to multiple myeloma specialists, autologous stem cell transplant is not going away any time soon, even in the age of new therapies. Dr. Sergio Giralt is a myeloma specialist and a transplant specialist who shares what "transplant plus" could look like. Now that new treatments and drugs are in the clinic, what is being done to extend remission times for patients by adding something else to the transplant, either before, during or after? Dr. Giral weighs in with options that include i...
Myeloma Crowd Radio: Nikoletta Lendvai, MD, PhD, Memorial Sloan Kettering
October 28, 2016 15:00 - 1 hour - 61.6 MBHow do clinical trials work in multiple myeloma? Dr. Nikoletta Lendvai of the Memorial Sloan Kettering Cancer Center joins us to share information how how trials work, how patients can join and why they benefit by participating. She will also describe open clinical trials at her center including a new drug called Selinexor. Listen in and learn why clinical trials can bring us closer to a cure, faster. Thanks to our episode sponsor, Takeda Oncology